Dual RAF-MEK Inhibitor Assessed

    Cancer Discovery
    |November 14, 2020
    PubMed
    Summary

    VS-6766, a novel dual RAF-MEK inhibitor, demonstrated safety and efficacy in early trials for solid tumors and multiple myeloma with RAS-RAF mutations.